InterMune raising $80M; Zogenix prices stock offering;

@FierceBiotech: Novartis R&D will ax 500 staffers, boost Boston in global realignment. More | Follow @FierceBiotech

@JohnCFierce: Geron shares double on imetelstat data. Quite a reversal of fortune for Geron. Story | Follow @JohnCFierce

@DamianFierce: Medtronic wins FDA approval to use its software with competitors' tech. More | Follow @DamianFierce

@EmilyMFierce: Next Generation: Cancer Drug in Disguise. Article | Follow @EmilyMFierce

> InterMune ($ITMN) says it expects to raise about $80 million from the sale of 6.5 million shares. Story

> San Diego-based Zogenix has priced an offering of 26.6 million shares at $2.25 each. Release

Medical Device News

@FierceMedDev: ICYMI: Roche's Ventana to concoct companion Dx tests for Incyte's cancer drugs. More | Follow @FierceMedDev

@MarkHFierce: Biocept becomes the latest Dx company to outline its IPO terms - full speed ahead. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Gold nanoparticles first to deliver RNA to brain tumors. More from FierceDrugDelivery | Follow @MichaelGFierce

> Surefire bags $18.2M for cancer-treating catheters. More

> Bacterin turns to distributor for European expansion. Item

> Investors elated over HeartWare's stellar Q3 heart pump sales. Article

> Medtronic wins FDA nod to use software with competitors' tech. Story

Pharma News

@FiercePharma: Biggest new news online: Will Merck be next to join Big Pharma's asset sale parade? Story | Follow @FiercePharma

@CarlyHFierce: Does the Justice Department's off-label marketing enforcement actually deter bad behavior? With GSK, maybe. More | Follow @CarlyHFierce

> J&J whistleblowers to collect record $168M share of DoJ settlement. Story

> Roche's new Gazyva beats predecessor Rituxan in staving off CLL. News

> Top Adcock shareholder nixes CFR offer, endangering $1.3B deal. More

Pharma Manufacturing News

> Hospira CEO looks to better days as 'swamp draining' nears end. News

> Wholesaler McKesson settles another price-manipulation suit. Article

> FDA finally lifts warning letter on AMRI fill/finish facility. More

> Visa woes still stalling FDA plans for China inspections. Story

> Pfizer contractors testing new methods to clean up old production site. News

> Nosco hiring 51 staff for packaging and labeling plant. Item

Vaccines News

> Merck readies FDA submission for son of Gardasil. News

> Takeda, Boehringer invest to move CMV vaccine into clinic. Story

> European scientists join Sanofi, Pfizer in C. diff vaccine race. Article

> Study finds one HPV vaccine dose gives strong, durable immune response. News

> WHO massively scales up Middle East polio immunization plan. Story

> Shipping snafu prompts Navy review of vaccination procedures. Item

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.